Seeking Alpha

Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles

Vertex's VX-548 shows promising efficacy and safety in neuropathic pain management, potentially outperforming Lyrica. Q3 financials are strong: 6% revenue growth, 87.16% gross profit margin, driven by ...
Nasdaq

Can Vertex Make Billions With a New Game-Changing Treatment? The Answer May Be Just Ahead

Vertex Pharmaceuticals (NASDAQ: VRTX) brings in billions of dollars in annual profit and revenue from its four cystic fibrosis (CF) treatments. The company is doing so well that, during this week's ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 10 Years?

The past decade has been a game-changing one for Vertex Pharmaceuticals (VRTX +1.63%). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained ...
The Motley Fool

This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?

Vertex already has generated billions of dollars in earnings from its cystic fibrosis portfolio. It's important to first look at why Vertex's CF drugs are so successful. In CF, mutations in the cystic ...
Kotaku

Shin Megami Tensei Vertex

All the Latest Game Footage and Images from Shin Megami Tensei Vertex This is a fangame based on Atlus's franchise, Shin Megami Tensei. All of this made on RPG Maker MV. This game has the purpose to ...